Controlling CAR T Cell Activity and Specificity with Synthetic SparX Adapters

Researchers developed a controllable cell therapy where synthetic D-Domain-containing proteins (SparX) bind one or more tumor antigens and mark those cells for elimination by genetically modified T cells